The increase in the average 12-month price target to $87.00 from previous targets suggests a bullish outlook from analysts, despite the diversity in opinions. Edwards Lifesciences' strong financial indicators, such as a high net margin and revenue growth, alongside its leadership in the medical devices sector, likely contribute to this positive sentiment. The range of analyst actions, from raising to lowering ratings, indicates varied expectations but the overall upward revision in price targets suggests confidence in the company's future performance.